Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways

被引:69
作者
Lan, H. [1 ]
Lin, H. V. [1 ]
Wang, C. F. [1 ]
Wright, M. J. [1 ]
Xu, S. [1 ]
Kang, L. [1 ]
Juhl, K. [1 ]
Hedrick, J. A. [2 ]
Kowalski, T. J. [1 ]
机构
[1] Merck Res Labs, Diabet & Endocrinol, Rahway, NJ 07065 USA
[2] Merck Res Labs, Biol, Rahway, NJ 07065 USA
关键词
GPR119; GLP-1; insulin; glucose; cAMP; calcium influx; GLUCAGON-LIKE PEPTIDE-1; PROTEIN-COUPLED RECEPTOR; INSULIN-SECRETION; GLYCEMIC CONTROL; LINE; OLEOYLETHANOLAMIDE; DISCOVERY; RELEASE;
D O I
10.1111/j.1476-5381.2011.01754.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND AND PURPOSE The G protein-coupled receptor 119 (GPR119) mediates insulin secretion from pancreatic beta cells and glucagon-like peptide 1 (GLP-1) release from intestinal L cells. While GPR119-mediated insulin secretion is glucose dependent, it is not clear whether or not GPR119-mediated GLP-1 secretion similarly requires glucose. This study was designed to address the glucose-dependence of GPR119-mediated GLP-1 secretion, and to explore the cellular mechanisms of hormone secretion in L cells versus those in beta cells. EXPERIMENTAL APPROACH GLP-1 secretion in response to GPR119 agonists and ion channel modulators, with and without glucose, was analysed in the intestinal L cell line GLUTag, in primary intestinal cell cultures and in vivo. Insulin secretion from Min6 cells, a pancreatic beta cell line, was analysed for comparison. KEY RESULTS In GLUTag cells, GPR119 agonists stimulated GLP-1 secretion both in the presence and in the absence of glucose. In primary mouse colon cultures, GPR119 agonists stimulated GLP-1 secretion under glucose-free conditions. Moreover, a GPR119 agonist increased plasma GLP-1 in mice without a glucose load. However, in Min6 cells, GPR119-mediated insulin secretion was glucose-dependent. Among the pharmacological agents tested in this study, nitrendipine, an L-type voltage-dependent calcium channel blocker, dose-dependently reduced GLP-1 secretion from GLUTag cells, but had no effect in Min6 cells in the absence of glucose. CONCLUSIONS AND IMPLICATIONS Unlike that in pancreatic beta cells, GPR119-mediated GLP-1 secretion from intestinal L cells was glucose-independent in vitro and in vivo, probably because of a higher basal calcium tone in the L cells.
引用
收藏
页码:2799 / 2807
页数:9
相关论文
共 20 条
  • [1] Special Issue: Guide to Receptors and Channels, 5th Edition Abstracts
    Alexander, Stephen P. H.
    Mathie, Alistair
    Peters, John A.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 : S1 - +
  • [2] A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release
    Chu, Zhi-Liang
    Carroll, Chris
    Alfonso, Jean
    Gutierrez, Veronica
    He, Hongmei
    Lucman, Annette
    Pedraza, Melinda
    Mondala, Helen
    Gao, Hui
    Bagnol, Didier
    Chen, Ruoping
    Jones, Robert M.
    Behan, Dominic P.
    Leonard, James
    [J]. ENDOCRINOLOGY, 2008, 149 (05) : 2038 - 2047
  • [3] A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release
    Chu, Zhi-Liang
    Jones, Robert M.
    He, Hongmei
    Carroll, Chris
    Gutierrez, Veronica
    Lucman, Annette
    Moloney, Molly
    Gao, Hui
    Mondala, Helen
    Bagnol, Didier
    Unett, David
    Liang, Yin
    Demarest, Keith
    Semple, Graeme
    Behan, Dominic P.
    Leonard, James
    [J]. ENDOCRINOLOGY, 2007, 148 (06) : 2601 - 2609
  • [4] The biology of incretin hormones
    Drucker, DJ
    [J]. CELL METABOLISM, 2006, 3 (03) : 153 - 165
  • [5] A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line
    Gribble, FM
    Williams, L
    Simpson, AK
    Reimann, F
    [J]. DIABETES, 2003, 52 (05) : 1147 - 1154
  • [6] Pathways in β-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues
    Henquin, JC
    [J]. DIABETES, 2004, 53 : S48 - S58
  • [7] Jones R. M., 2005, WO Pat. Appl., Patent No. 2005121121
  • [8] GPR119 agonists for the treatment of type 2 diabetes
    Jones, Robert M.
    Leonard, James N.
    Buzard, Daniel J.
    Lehmann, Juerg
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (10) : 1339 - 1359
  • [9] GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis
    Lan, Hong
    Vassileva, Galya
    Corona, Aaron
    Liu, Li
    Baker, Hana
    Golovko, Andrei
    Abbondanzo, Susan J.
    Hu, Weiwen
    Yang, Shijun
    Ning, Yun
    Del Vecchio, Robert A.
    Poulet, Frederique
    Laverty, Maureen
    Gustafson, Eric L.
    Hedrick, Joseph A.
    Kowalski, Timothy J.
    [J]. JOURNAL OF ENDOCRINOLOGY, 2009, 201 (02) : 219 - 230
  • [10] GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell
    Lauffer, Lina M.
    Lakoubov, Roman
    Brubaker, Patricia L.
    [J]. DIABETES, 2009, 58 (05) : 1058 - 1066